Figure 5. Proposed algorithm to treat early, intermediate and advanced disease (based on the number of previous lines).

^*In Brazil, pomalidomide is not available (PCd, KPd, DPd, VPd and Pd are alternative options). IRd and ERd have a significant effect on PFS in patients with second and third previous lines not refractory to lenalidomide and preferably sensitive to bortezomib [13–15, 31, 86]. Patients who relapse after ≥ 2 years are considered sensitive.